Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting

(1) Background Immune checkpoint inhibitors (ICIs) have recently become an important therapeutic option for patients with advanced urothelial carcinoma (aUC). Avelumab is an anti-PD-L1 (programmed cell death ligand 1) antibody that restores antitumor T-cell immune function by blocking the binding of...

Повний опис

Бібліографічні деталі

Автори:	Rossella De Luca, Pasquale Vitale, Alessio Pepe, Roberta Spedaliere, Alchiede Simonato, Raffaele Addeo, Giuseppe Cicero
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2024-11-01
Серія:	Scientia Pharmaceutica
Предмети:	Avelumab immunotherapy advanced urothelial carcinoma progression free survival quality of life
Онлайн доступ:	https://www.mdpi.com/2218-0532/92/4/62
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!